Oksana Kaidanovich-Beilin

Oksana Kaidanovich-Beilin

Auto-generated profile, based on publicly available information

Oksana Kaidanovich-Beilin

Samuel Lunenfeld Research Institute, Mount Sinai Hospital Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
OKOksana Kaidanovich-Beilin
Oksana Kaidanovich-Beilin
JWJames Robert Woodgett
James Robert Woodgett
Glycogen synthase kinase-3 (GSK-3) is a widely expressed and highly conserved serine/threonine protein kinase encoded in mammals by two genes that generate two related proteins: GSK-3α and GSK-3β. GSK-3 is active in cells under resting conditions and is primarily regulated through inhibition or diversion of its activity. While GSK-3 is one of the few protein kinases that can be inactivated by phosphorylation, the mechanisms of GSK-3 regulation are more varied and not fully understood. Precise control appears to be achieved by a combination of phosphorylation, localization, and sequestration by a number of GSK-3-binding proteins. GSK-3 lies downstream of several major signaling pathways including the phosphatidylinositol 3′ kinase pathway, the Wnt pathway, Hedgehog signaling and Notch. Specific pools of GSK-3, which differ in intracellular localization, binding partner affinity, and relative amount are differentially sensitized to several distinct signaling pathways and these sequestration mechanisms contribute to pathway insulation and signal specificity. Dysregulation of signaling pathways involving GSK-3 is associated with the pathogenesis of numerous neurological and psychiatric disorders and there are data suggesting GSK-3 isoform-selective roles in several of these. Here, we review the current knowledge of GSK-3 regulation and targets and discuss the various animal models that have been employed to dissect the functions of GSK-3 in brain development and function through the use of conventional or conditional knockout mice as well as transgenic mice. These studies have revealed fundamental roles for these protein kinases in memory, behavior, and neuronal fate determination and provide insights into possible therapeutic interventions.

25 February 2011 in Journal of Visualized Experiments
Verified
Journal Article
Open access
PDF file
OKOksana Kaidanovich-Beilin
Oksana Kaidanovich-Beilin
TLTatiana Lipina
Tatiana Lipina
IVIgor Vukobradovic
Igor Vukobradovic
JRJohn Roder
John Roder
JWJames R. Woodgett
James R. Woodgett
Social interactions are a fundamental and adaptive component of the biology of numerous species. Social recognition is critical for the structure and stability of the networks and relationships that define societies. For animals, such as mice, recognition of conspecifics may be important for maintaining social hierarchy and for mate choice 1. A variety of neuropsychiatric disorders are characterized by disruptions in social behavior and social recognition, including depression, autism spectrum disorders, bipolar disorders, obsessive-compulsive disorders, and schizophrenia. Studies of humans as well as animal models (e.g., Drosophila melanogaster, Caenorhabditis elegans, Mus musculus, Rattus norvegicus) have identified genes involved in the regulation of social behavior 2. To assess sociability in animal models, several behavioral tests have been developed (reviewed in 3). Integrative research using animal models and appropriate tests for social behavior may lead to the development of improved treatments for social psychopathologies. The three-chamber paradigm test known as Crawley's sociability and preference for social novelty protocol has been successfully employed to study social affiliation and social memory in several inbred and mutant mouse lines (e.g. 4-7). The main principle of this test is based on the free choice by a subject mouse to spend time in any of three box's compartments during two experimental sessions, including indirect contact with one or two mice with which it is unfamiliar. To quantitate social tendencies of the experimental mouse, the main tasks are to measure a) the time spent with a novel conspecific and b) preference for a novel vs. a familiar conspecific. Thus, the experimental design of this test allows evaluation of two critical but distinguishable aspects of social behavior, such as social affiliation/motivation, as well as social memory and novelty. "Sociability" in this case is defined as propensity to spend time with another mouse, as compared to time spent alone in an identical but empty chamber 7. "Preference for social novelty" is defined as propensity to spend time with a previously unencountered mouse rather than with a familiar mouse 7. This test provides robust results, which then must be carefully analyzed, interpreted and supported/confirmed by alternative sociability tests. In addition to specific applications, Crawley's sociability test can be included as an important component of general behavioral screen of mutant mice.

1 April 2004 in Biological Psychiatry
Verified
Journal Article
Closed access
OKOksana Kaidanovich-Beilin
Oksana Kaidanovich-Beilin
AMAnat Milman
Anat Milman
Abraham WeizmanAbraham Weizman
Abraham Weizman
CPChaim G Pick
Chaim G Pick
Hagit Eldar-FinkelmanHagit Eldar-Finkelman
Hagit Eldar-Finkelman

19 November 2009 in Molecular Brain
Verified
Journal Article
Open access
PDF file
OKOksana Kaidanovich-Beilin
Oksana Kaidanovich-Beilin
TLTatiana V Lipina
Tatiana V Lipina
KTKeizo Takao
Keizo Takao
MEMatthijs van Eede
Matthijs van Eede
SHSatoko Hattori
Satoko Hattori
JWJames R Woodgett
James R Woodgett
Background: Glycogen synthase kinase-3 (GSK-3) is a widely expressed and highly conserved serine/threonine protein kinase encoded by two genes that generate two related proteins: GSK-3α and GSK-3β. Mice lacking a functional GSK-3α gene were engineered in our laboratory; they are viable and display insulin sensitivity. In this study, we have characterized brain functions of GSK-3α KO mice by using a well-established battery of behavioral tests together with neurochemical and neuroanatomical analysis.Results: Similar to the previously described behaviours of GSK-3β+/-mice, GSK-3α mutants display decreased exploratory activity, decreased immobility time and reduced aggressive behavior. However, genetic inactivation of the GSK-3α gene was associated with: decreased locomotion and impaired motor coordination, increased grooming activity, loss of social motivation and novelty; enhanced sensorimotor gating and impaired associated memory and coordination. GSK-3α KO mice exhibited a deficit in fear conditioning, however memory formation as assessed by a passive avoidance test was normal, suggesting that the animals are sensitized for active avoidance of a highly aversive stimulus in the fear-conditioning paradigm. Changes in cerebellar structure and function were observed in mutant mice along with a significant decrease of the number and size of Purkinje cells.Conclusion: Taken together, these data support a role for the GSK-3α gene in CNS functioning and possible involvement in the development of psychiatric disorders.

1 July 2002 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RIRonit Ilouz
Ronit Ilouz
OKOksana Kaidanovich
Oksana Kaidanovich
DGDavid Gurwitz
David Gurwitz
Hagit Eldar-FinkelmanHagit Eldar-Finkelman
Hagit Eldar-Finkelman

1 June 2003 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
BPBatya Plotkin
Batya Plotkin
OKOksana Kaidanovich
Oksana Kaidanovich
ITIlana Talior
Ilana Talior
Hagit Eldar-FinkelmanHagit Eldar-Finkelman
Hagit Eldar-Finkelman
Glycogen synthase kinase-3 (GSK-3) was shown to be a key factor in attenuation of the cellular action of insulin. We speculated that inhibition of GSK-3 might have a potential therapeutic value in treatment of insulin resistance and type 2 diabetes. Here, we present a novel class of specific phosphorylated peptides inhibitors of GSK-3, which in sharp contrast to other protein kinase inhibitors that are ATP analogs, are substrate-competitive. We show that the GSK-3 peptide inhibitor activated glycogen synthase activity 2.5-fold in human embryonic kidney 293 cells, and increased glucose uptake in primary mouse adipocytes in the absence or presence of insulin compared with cells treated with two respective peptide controls. In addition, an i.p. administration of GSK-3 peptide inhibitor to normal or insulin-resistant obese C57BL/6J mice, improved their performance on glucose tolerance tests compared with control-treated animals. We present here a novel rational strategy for developing specific GSK-3 inhibitors and point toward GSK-3 as a promising therapeutic target in insulin resistance and type-2 diabetes.